Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia.

被引：0
|
作者：
Kamatani, N
Fujimori, S
Hada, T
Hosoya, T
Matsuzawa, Y
Ueda, T
Yamanaka, H
Kato, R
机构：
[1] Tokyo Womens Med Univ, Shinjuku Ku, Tokyo, Japan
[2] Teikyo Univ, Sch Med, Itabashi Ku, Tokyo, Japan
[3] Hyogo Med Univ, Nishinomiya, Hyogo, Japan
[4] Jikei Univ, Sch Med, Minato Ku, Tokyo, Japan
[5] Sumitomo Hosp, Kita Ku, Osaka, Japan
[6] Univ Fukui, Matsuoka, Fukui, Japan
[7] Keio Univ, Shinjuku Ku, Tokyo, Japan
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S336 / S337
页数：2
相关论文
共 42 条
  • [1] Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a Phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia.
    Kamatani, N
    Fujimori, S
    Hada, T
    Hosoya, T
    Matsuzawa, Y
    Ueda, J
    Yamanaka, H
    Kato, R
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S337 - S337
  • [2] Febuxostat: A Novel Non-Purine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Gout
    Yu, Kuang-Hui
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 69 - 75
  • [3] Long-term safety and efficacy of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in subjects with hyperuricemia and gout
    Schumacher, HR
    Wortmann, R
    Becker, M
    MacDonald, P
    Palo, W
    Streit, J
    Lademacher, C
    Joseph-Ridge, N
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 498 - 498
  • [4] Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients.
    Becker, MA
    Schumacher, R
    Wortmann, R
    MacDonald, P
    Palo, W
    Joseph-Ridge, N
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S336 - S336
  • [5] Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout
    Schumacher, HR
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (07) : 893 - 903
  • [6] Effect of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase, on the QT interval in healthy subjects
    Yu, P
    Khosravan, R
    MacDonald, P
    Joseph-Ridge, N
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1195 - 1195
  • [7] Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
    Takano, Y
    Hase-Aoki, K
    Horiuchi, H
    Zhao, L
    Kasahara, Y
    Kondo, S
    Becker, MA
    LIFE SCIENCES, 2005, 76 (16) : 1835 - 1847
  • [8] Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia
    Komoriya, K
    Hoshide, S
    Takeda, K
    Kobayashi, H
    Kubo, J
    Tsuchimoto, M
    Nakachi, T
    Yamanaka, H
    Kamatani, N
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1119 - 1122
  • [9] A safety and efficacy clinical trial of a novel nun-purine selective inhibitor of xanthine oxidase, febuxostat in subjects with gout
    Becker, MA
    Schumacher, H
    Wortmann, RL
    Joseph-Ridge, N
    Lademacher, C
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 60 - 60
  • [10] Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase.
    Wortmann, R
    Becker, MA
    Schumacher, HR
    MacDonald, P
    Palo, WA
    Joseph-Ridge, N
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S335 - S336
12345